220 related articles for article (PubMed ID: 24315763)
1. Involvement of HLA class I molecules in the immune escape of urologic tumors.
Carretero R; Gil-Julio H; Vázquez-Alonso F; Garrido F; Castiñeiras J; Cózar JM
Actas Urol Esp; 2014 Apr; 38(3):192-9. PubMed ID: 24315763
[TBL] [Abstract][Full Text] [Related]
2. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
3. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
4. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
Aptsiauri N; Carretero R; Garcia-Lora A; Real LM; Cabrera T; Garrido F
Cancer Immunol Immunother; 2008 Nov; 57(11):1727-33. PubMed ID: 18491093
[TBL] [Abstract][Full Text] [Related]
5. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells.
Giorda E; Sibilio L; Martayan A; Moretti S; Venturo I; Mottolese M; Ferrara GB; Cappellacci S; Eibenschutz L; Catricalà C; Grammatico P; Giacomini P
Cancer Res; 2003 Jul; 63(14):4119-27. PubMed ID: 12874016
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.
Carretero R; Cabrera T; Gil H; Saenz-Lopez P; Maleno I; Aptsiauri N; Cozar JM; Garrido F
Int J Cancer; 2011 Aug; 129(4):839-46. PubMed ID: 20957629
[TBL] [Abstract][Full Text] [Related]
7. Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F; Aptsiauri N
Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
[TBL] [Abstract][Full Text] [Related]
8. Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer.
Kitamura H; Torigoe T; Honma I; Sato E; Asanuma H; Hirohashi Y; Sato N; Tsukamoto T
Clin Cancer Res; 2006 Aug; 12(15):4641-4. PubMed ID: 16899613
[TBL] [Abstract][Full Text] [Related]
9. Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
Gil-Julio H; Perea F; Rodriguez-Nicolas A; Cozar JM; González-Ramirez AR; Concha A; Garrido F; Aptsiauri N; Ruiz-Cabello F
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298868
[TBL] [Abstract][Full Text] [Related]
10. Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma.
Ibrahim EC; Allory Y; Commo F; Gattegno B; Callard P; Paul P
Am J Pathol; 2003 Feb; 162(2):501-8. PubMed ID: 12547708
[TBL] [Abstract][Full Text] [Related]
11. MHC heterogeneity and response of metastases to immunotherapy.
Algarra I; Garrido F; Garcia-Lora AM
Cancer Metastasis Rev; 2021 Jun; 40(2):501-517. PubMed ID: 33860434
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
13. HLA class I expression in bladder carcinomas.
Cabrera T; Pedrajas G; Cozar JM; Garrido A; Vicente J; Tallada M; Garrido F
Tissue Antigens; 2003 Oct; 62(4):324-7. PubMed ID: 12974799
[TBL] [Abstract][Full Text] [Related]
14. A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.
Sutoh Yoneyama M; Tobisawa Y; Hatakeyama S; Sato M; Tone K; Tatara Y; Kakizaki I; Funyu T; Fukuda M; Hoshi S; Ohyama C; Tsuboi S
J Biochem; 2017 Jun; 161(6):479-492. PubMed ID: 28011817
[TBL] [Abstract][Full Text] [Related]
15. HLA-E expression and its clinical relevance in human renal cell carcinoma.
Seliger B; Jasinski-Bergner S; Quandt D; Stoehr C; Bukur J; Wach S; Legal W; Taubert H; Wullich B; Hartmann A
Oncotarget; 2016 Oct; 7(41):67360-67372. PubMed ID: 27589686
[TBL] [Abstract][Full Text] [Related]
16. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
Angell TE; Lechner MG; Jang JK; LoPresti JS; Epstein AL
Clin Cancer Res; 2014 Dec; 20(23):6034-44. PubMed ID: 25294906
[TBL] [Abstract][Full Text] [Related]
17. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
18. Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.
Sabbatino F; Liguori L; Polcaro G; Salvato I; Caramori G; Salzano FA; Casolaro V; Stellato C; Col JD; Pepe S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023239
[TBL] [Abstract][Full Text] [Related]
19. Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy.
van Esch EM; Tummers B; Baartmans V; Osse EM; Ter Haar N; Trietsch MD; Hellebrekers BW; Holleboom CA; Nagel HT; Tan LT; Fleuren GJ; van Poelgeest MI; van der Burg SH; Jordanova ES
Int J Cancer; 2014 Aug; 135(4):830-42. PubMed ID: 24415578
[TBL] [Abstract][Full Text] [Related]
20. Tumour immunology, vaccination and escape strategies.
García-Lora A; Algarra I; Collado A; Garrido F
Eur J Immunogenet; 2003 Jun; 30(3):177-83. PubMed ID: 12786993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
